FIELD doc_type
{"evidence":[{"page_num":42,"heading":"10.6 (\"Insurance\")), Article 11 (\"Confidentiality, Press Releases and Publications\"),","snippet":"10.6 (\"Insurance\")), Article 11 (\"Confidentiality, Press Releases and Publications\"),"},{"page_num":37,"heading":null,"snippet":"11.3 Duration. The confidentiality and non-use obligations contained in this Agreement shall continue for the duration of this Agreement and for a period of [**] ([**]) years after termination"}],"confidence":0.62,"value":"msa"}

FIELD party_a_name
{"evidence":[{"page_num":61,"heading":"By:     Print Name:     Title:","snippet":"EKR Therapeutics, Inc."}],"confidence":0.42,"value":"EKR Therapeutics, Inc."}

FIELD party_b_name
{"evidence":[{"page_num":61,"heading":"By:     Print Name:     Title:","snippet":"EKR Therapeutics, Inc."}],"confidence":0.62,"value":"EKR Therapeutics, Inc."}

FIELD effective_date
{"evidence":[{"page_num":1,"heading":"MARKETING AGREEMENT","snippet":"...is made on October 15, 2009 (the \"Agreement Date\") and is effective as of the Effective Date (as defined below)..."}],"confidence":0.22,"value":null}

FIELD term_length
{"evidence":[{"page_num":8,"heading":null,"snippet":"\"Term\"   Means the term of this Agreement as set out in Section 15;"},{"page_num":39,"heading":"14.4 Non Participation. Should in accordance with Section 14.2, PPI decide not to","snippet":"As used herein \"Term\" refers to the Initial Term and any renewal terms."}],"confidence":0.18,"value":null}

FIELD governing_law
{"evidence":[{"page_num":63,"heading":null,"snippet":"This Note shall be governed by and construed in accordance with the laws of the State of New York"},{"page_num":49,"heading":"21.10 Cumulative Rights. The rights and remedies of each of the Parties under or pursuant","snippet":"21.13 Governing Law. This Agreement and the relationship between the Parties shall be governed by, and interpreted in accordance with New York law"}],"confidence":0.98,"value":"New York"}

FIELD termination_notice_days
{"evidence":[{"page_num":42,"heading":null,"snippet":"EKR may terminate this Agreement for convenience at any time upon [**] ([**]) days prior, written notice to PPI."}],"confidence":0.32,"value":null}

FIELD liability_cap
{"evidence":[{"page_num":35,"heading":"10.8 PPI Liability Limitation. Any and all liability of PPI to EKR howsoever arising in","snippet":"Any and all liability of PPI to EKR howsoever arising... shall be limited ... to [**] US Dollars ($[**]);"},{"page_num":36,"heading":"7.2.12 of  the Supply Agreement.   10.9 EKR Liability Limitation. Any and all liability of","snippet":"Any and all liability of EKR to PPI howsoever arising... shall be limited ... to [**] US Dollars ($[**]);"}],"confidence":0.62,"value":"[**] US Dollars ($[**])"}

FIELD non_solicit_clause_present
{"evidence":[{"page_num":37,"heading":null,"snippet":"11.3 Duration. The confidentiality and non-use obligations contained in this Agreement shall continue for the duration of this Agreement and for a period of [**] ([**]) years after termination"}],"confidence":0.18,"value":false}

FIELD data_transfer_outside_uk_eu
{"evidence":[{"page_num":3,"heading":"Confidential Information","snippet":"Means all confidential information, data and materials in whatever form disclosed by or on behalf of one Party  or its Affiliates to the other Party or its Affiliates"},{"page_num":17,"heading":null,"snippet":"The cost of submitting any data generated by any Phase IV studies conducted by EKR which is required to be filed with the FDA shall be borne by EKR"}],"confidence":0.22,"value":"unknown"}

FIELD risk_level
{"evidence":[{"page_num":35,"heading":"10.5 Settlement of Claims. The indemnified Party shall not admit liability in respect of,","snippet":"10.6 Insurance. Each Party shall maintain, at its own cost, comprehensive product liability insurance, general commercial liability insurance and business interruption insurance..."},{"page_num":16,"heading":null,"snippet":"During the Lease Term, PPI shall: (i) assume the risk of loss or damage to the Transferred Equipment; ... (v) maintain property damage and liability insurance..."}],"confidence":0.32,"value":"medium"}

FIELD risk_explanation
{"evidence":[{"page_num":16,"heading":null,"snippet":"During the Lease Term, PPI shall: (i) assume the risk of loss or damage to the Transferred Equipment; ... (v) maintain property damage and liability insurance and insurance against loss or damage"},{"page_num":16,"heading":null,"snippet":"If any of the Transferred Equipment is lost, stolen, destroyed, damaged beyond repair... PPI shall promptly... pay to EKR an amount equal to the estimated in-place, fair market value"},{"page_num":45,"heading":"18.2 Duration. If such Force Majeure continues unabated for a period of at least ninety","snippet":"If the affected Party is prevented... from performing... for a continuous period of six (6) months the other Party may terminate this Agreement."}],"confidence":0.62,"value":"The risk level is driven by provisions that place significant operational and financial exposure on PPI for the transferred equipment, including assuming risk of loss and maintaining insurance. If equipment is lost or destroyed, PPI must compensate EKR at fair market value, creating potentially material payment obligations. Additionally, prolonged force majeure can lead to termination after extended non-performance, adding continuity and termination risk."}